 LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 GLOBE NEWSWIRE -- Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH Mereo or the Company, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual RD day on Tuesday, November 24, to review the Companys key pipeline programs including etigilimab Anti-TIGIT for solid tumors and alvelestat for alpha-1 antitrypsin deficiency AATD and COVID-19 respiratory disease. The virtual RD day will feature external experts and will include a more detailed review of the etigilimab development program, including the design and biomarker strategy for the recently initiated Phase 1b2 basket combination study. 